Literature DB >> 3492026

Complement (C3) metabolism in systemic lupus erythematosus in relation to the disease course.

A J Swaak, A van Rooyen, C Vogelaar, M Pillay, E Hack.   

Abstract

Metabolic turnover studies of complement components (C3) provide a direct insight into the dynamics of the complement regulation (synthesis and catabolism). To obtain information about the role of the complement system in relation to the disease course in patients with systemic lupus erythematosus (SLE), a prospective study was performed. The results of the C3 turnover studies were also correlated to the complement levels (C3) and to the presence of C3 conversion products (C3d) in circulation. In nearly all SLE patients (in 21 of the 26 metabolic turnover studies) a C3 hypercatabolism was found, with a quantitative difference depending on the disease phase. In the period preceding an exacerbation an impaired C3 synthesis was observed (in three of the four studies), in contrast to SLE patients in stable disease phase where in one case only a decrease C3 synthesis was calculated (1 out of 15 observations). A linear correlation was found between the serum C3-levels and the ratio of C3d/C3, suggesting that both serologic parameters are quantitatively indicative for C3 hypercatabolism. The study shows that in all SLE patients, irrespective of the disease stage, an increased C3 consumption is found, which supports the concept that a chronic inflammatory process is constantly present.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3492026     DOI: 10.1007/BF00541371

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

1.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

2.  Immunology of DNA. IV. Quantitative aspects of the Farr assay.

Authors:  L A Aarden; F Lakmaker; E R De Groot
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

3.  The in vivo metabolism of the third component of complement in systemic lupus erythematosus.

Authors:  L D Petz; R Powers; J R Fries; N R Cooper; H R Holman
Journal:  Arthritis Rheum       Date:  1977 Sep-Oct

4.  Serum complement component levels in human glomerulonephritis.

Authors:  E J Lewis; C B Carpenter; P H Schur
Journal:  Ann Intern Med       Date:  1971-10       Impact factor: 25.391

5.  Significance of persisting serologic abnormalities in SLE.

Authors:  R W Lightfoot; G R Hughes
Journal:  Arthritis Rheum       Date:  1976 Sep-Oct

6.  Properdin levels in systemic lupus erythematosus and membranoproleferative glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  Clin Exp Immunol       Date:  1974-04       Impact factor: 4.330

7.  Studies of serum complement in the hypocomplementaemic nephritides.

Authors:  D G Williams; D K Peters; J Fallows; A Petrie; O Kourilsky; L Morel-Maroger; J S Cameron
Journal:  Clin Exp Immunol       Date:  1974-11       Impact factor: 4.330

8.  Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes.

Authors:  A J Swaak; A Hannema; C Vogelaar; F A Boom; L van Es; R van Aalst; L W Statius van Eps
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

9.  Correlation between levels of breakdown products of C3, C4, and properdin factor B in synovial fluids from patients with rheumatoid arthritis.

Authors:  L H Perrin; U E Nydegger; R H Zubler; P H Lambert; P A Miescher
Journal:  Arthritis Rheum       Date:  1977-03

10.  The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.

Authors:  H J Müllerèberhard; A P Dalmasso; M A Calcott
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

View more
  13 in total

Review 1.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

2.  Relation between serological data at the time of biopsy and renal histology in lupus nephritis.

Authors:  J C Nossent; S C Henzen-Logmans; T M Vroom; V Huysen; J H Berden; A J Swaak
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

3.  Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.

Authors:  V A Makinde; G Senaldi; A S Jawad; H Berry; D Vergani
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

4.  Complement in type 1 (insulin-dependent) diabetes.

Authors:  G Senaldi; B A Millward; M J Hussein; D Pyke; R D Leslie; D Vergani
Journal:  Diabetologia       Date:  1987-10       Impact factor: 10.122

5.  Distribution of the HindIII restriction fragment length polymorphism among patients with systemic lupus erythematosus with different concentrations of CR1.

Authors:  H Satoh; E Yokota; K Tokiyama; T Kawaguchi; Y Niho
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

6.  Significance of low molecular weight C1q in systemic lupus erythematosus.

Authors:  R Hoekzema; A J Swaak; M C Brouwer; A van Rooijen; E J Nieuwenhuys; C E Hack
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

Review 7.  Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus.

Authors:  A J Swaak; V Huysen; J C Nossent; R J Smeenk
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

8.  Reply.

Authors:  Alfred H J Kim; Vibeke Strand; John P Atkinson
Journal:  Arthritis Rheumatol       Date:  2019-07-19       Impact factor: 10.995

9.  Complement (C3) metabolism in rheumatoid arthritis in relation to the disease course.

Authors:  A J Swaak; H Han; A van Rooyen; M Pillay; C E Hack
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

10.  Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.

Authors:  G Senaldi; V A Makinde; D Vergani; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.